on GENSIGHT BIOLOGICS S.A. (EPA:SIGHT)
GenSight Biologics Reports 2025 Financial Performance
GenSight Biologics has released its estimated consolidated financial results for 2025. The year marked a significant pivot for the biopharma company, achieving key regulatory milestones. Furthermore, the company projects its cash runway to last until December 2026, amid preparations for the Phase III RECOVER study.
Financially, GenSight recorded an operating income of €0.7 million, reflecting a decline from €2.6 million in 2024 due to reduced research tax credits. The operating loss decreased by 30.1% to €11.1 million, attributed to decreased research and development expenses, which fell by 47.9%.
Despite a challenging fundraising environment, GenSight completed several financing rounds. Net cash flows from financing were €8.9 million, down from €13.5 million in 2024. However, they successfully extended their financial runway by securing various capital increases throughout the year.
Looking ahead, though revenues from early access programs are anticipated to cover operational expenses, additional funding will be necessary for the upcoming Phase III clinical trial.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all GENSIGHT BIOLOGICS S.A. news